力生制药 (002393.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.3x

Market Cap

CNY 4.26B

MomentumView details →

1D Return

−4.16%

YTD Return

−35.61%

RSI (14)

42.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.3x

Market Cap

CNY 4.26B

RSI (14)

42.7

MomentumView details →

1D Return

−4.16%

YTD Return

−35.61%

ProfitabilityView details →

Gross Margin

54.52%

Net Margin

30.48%

EBITDA Margin

40.24%

ROE (TTM)

8.96%

ROA (TTM)

7.46%

Asset Turnover

0.24x

GrowthView details →

Revenue YoY

+0.99%

EPS YoY

+128.93%

FCF YoY

+621.13%

Revenue CAGR 3Y

+6.68%

EPS CAGR 3Y

+47.00%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.09

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

4.52x

Quick Ratio

4.22x

Div Yield

7.30%

Div Rate

CNY 1.02

Div Growth 1Y

+191.43%

Financials snapshotView financials →

Revenue (TTM)

1.35B

Net Income (TTM)

412.89M

Op. CF (TTM)

249.46M

Latest newsMore news →

Lisheng Pharmaceutical announced its first-half 2026 results: revenue of 642 million yuan, down 12.29% year-on-year; net profit attributable to shareholders of 78.326 million yuan, down 77.16% year-on-year.16d ago

Similar companies

阳谷华泰300121.SZ 万集科技300552.SZ 东港股份002117.SZ 洁雅股份301108.SZ 王子新材002735.SZ 家联科技301193.SZ Find similar companies →

Latest newsMore news →

Lisheng Pharmaceutical announced its first-half 2026 results: revenue of 642 million yuan, down 12.29% year-on-year; net profit attributable to shareholders of 78.326 million yuan, down 77.16% year-on-year.16d ago